Ad
related to: what is gaucher's disease- Prescribing Information
Efficacy and safety information
Learn about Cerdelga
- Dosing Guide
Dosing information for HCPs
Medication guide for Cerdelga
- Phase III Clinical Data
Read our Phase III trial results
Primary and open-label extension
- Clinical Results
Explore primary and extension data
See key safety information. ENCORE
- Prescribing Information
Search results
Results From The WOW.Com Content Network
The National Gaucher Foundation (United States) states the incidence of Gaucher's disease is about one in 20,000 live births. [39] Around one in 100 people in the general US population is a carrier for type I Gaucher's disease, giving a prevalence of one in 40,000. [ 40 ]
Enzyme replacement therapy is available to treat mainly Fabry disease and Gaucher disease, and people with these types of sphingolipidoses may live well into adulthood. The other types are generally fatal by age 1 to 5 years for infantile forms, but progression may be mild for juvenile- or adult-onset forms.
Enzyme replacement therapy is available mainly to treat Fabry disease and Gaucher disease and people with these types of sphingolipidoses may live well into adulthood. Generally, the other types are fatal by age 1 to 5 years for infantile forms, but progression may be mild for juvenile-onset or adult-onset forms.
The hematology specialist officially diagnosed me with Gaucher disease. The bone marrow biopsy confirmed my diagnosis of Gaucher disease—given that it’s genetic, it showed up in my DNA on the ...
A defect in the degradation of glucocerebrosides is Gaucher's disease. The corresponding defects for galactocerebrosides are: a) Ceramide trihexoside (globotriaosylceramide) accumulation – Fabry's disease. Clinical features include acroparaesthesia (tingling, pins and needles sensation in the extremities) [3]
In Gaucher's disease, the enzyme glucocerebrosidase is nonfunctional and cannot break down glucocerebroside into glucose and ceramide in the lysosome. [1] Affected macrophages, called Gaucher cells, have a distinct appearance similar to "wrinkled tissue paper" under light microscopy, because the substrates build-up within the lysosome.
ERT is available for some lysosomal storage diseases: Gaucher disease, Fabry disease, MPS I, MPS II (Hunter syndrome), MPS VI and Pompe disease. [1] ERT does not correct the underlying genetic defect, but it increases the concentration of the enzyme that the patient is lacking. [ 1 ]
Imiglucerase is a medication used in the treatment of Gaucher's disease. [2] [3]It is a recombinant DNA-produced analogue of the human enzyme β-glucocerebrosidase. Cerezyme is a freeze-dried medicine containing imiglucerase, manufactured by Genzyme Corporation.